Iron Supplementation of Marginally Low Birth Weight Infants

NCT ID: NCT00558454

Last Updated: 2020-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

380 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Iron is essential for brain development and there is a well established association between iron deficiency in infants and poor neurological development. In Sweden, about 5% of newborns have low birth weight (\< 2500 g). Due to small iron stores at birth and rapid postnatal growth, they have increased risk of iron deficiency and it is therefore important to prevent iron deficiency in this population. However, excessive iron supplementation can have adverse effects in infants such as growth impairment. In a randomized, controlled trial, we are investigating the effects of 0, 1 or 2 mg/kg/d of iron on brain myelination, cognitive development and growth in low birth weight infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Iron-Deficiency Child Behavior Disorders Cognitive Manifestations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Placebo

Group Type PLACEBO_COMPARATOR

Iron

Intervention Type DRUG

Ferrous succinate mixture

2

1 mg/kg/day from age 6 weeks to 6 months

Group Type EXPERIMENTAL

Iron

Intervention Type DRUG

Ferrous succinate mixture

3

2 mg/kg/day from age 6 weeks to 6 months

Group Type EXPERIMENTAL

Iron

Intervention Type DRUG

Ferrous succinate mixture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iron

Ferrous succinate mixture

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ferromyn S, AstraZeneca, Södertälje, Sweden

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Marginally low birth weight (2000-2500 g)
* Healthy at inclusion(6 weeks of age)
* No previous blood transfusion
* No previous iron supplementation

Exclusion Criteria

* Anemia at inclusion
Minimum Eligible Age

39 Days

Maximum Eligible Age

45 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)

OTHER_GOV

Sponsor Role collaborator

Jerring Foundation, Sweden

UNKNOWN

Sponsor Role collaborator

Oskar Foundation

OTHER

Sponsor Role collaborator

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Magnus Domellöf

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Magnus Domellöf, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Umeå University, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karolinska Hospital (including Danderyd Hospital)

Stockholm, , Sweden

Site Status

Umeå University Hospital

Umeå, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Lindberg J, Norman M, Westrup B, Domellof M, Berglund SK. Lower systolic blood pressure at age 7 y in low-birth-weight children who received iron supplements in infancy: results from a randomized controlled trial. Am J Clin Nutr. 2017 Aug;106(2):475-480. doi: 10.3945/ajcn.116.150482. Epub 2017 Jun 28.

Reference Type DERIVED
PMID: 28659293 (View on PubMed)

Lindberg J, Norman M, Westrup B, Ohrman T, Domellof M, Berglund SK. Overweight, Obesity, and Body Composition in 3.5- and 7-Year-Old Swedish Children Born with Marginally Low Birth Weight. J Pediatr. 2015 Dec;167(6):1246-52.e3. doi: 10.1016/j.jpeds.2015.08.045. Epub 2015 Sep 26.

Reference Type DERIVED
PMID: 26394823 (View on PubMed)

Berglund SK, Westrup B, Domellof M. Iron supplementation until 6 months protects marginally low-birth-weight infants from iron deficiency during their first year of life. J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):390-5. doi: 10.1097/MPG.0000000000000633.

Reference Type DERIVED
PMID: 25406528 (View on PubMed)

Berglund SK, Lindberg J, Westrup B, Domellof M. Effects of iron supplements and perinatal factors on fetal hemoglobin disappearance in LBW infants. Pediatr Res. 2014 Nov;76(5):477-82. doi: 10.1038/pr.2014.116. Epub 2014 Aug 13.

Reference Type DERIVED
PMID: 25119339 (View on PubMed)

Berglund SK, Westrup B, Hagglof B, Hernell O, Domellof M. Effects of iron supplementation of LBW infants on cognition and behavior at 3 years. Pediatrics. 2013 Jan;131(1):47-55. doi: 10.1542/peds.2012-0989. Epub 2012 Dec 10.

Reference Type DERIVED
PMID: 23230066 (View on PubMed)

Berglund S, Lonnerdal B, Westrup B, Domellof M. Effects of iron supplementation on serum hepcidin and serum erythropoietin in low-birth-weight infants. Am J Clin Nutr. 2011 Dec;94(6):1553-61. doi: 10.3945/ajcn.111.013938. Epub 2011 Nov 9.

Reference Type DERIVED
PMID: 22071701 (View on PubMed)

Berglund S, Westrup B, Domellof M. Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants. Pediatrics. 2010 Oct;126(4):e874-83. doi: 10.1542/peds.2009-3624. Epub 2010 Sep 6.

Reference Type DERIVED
PMID: 20819898 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Iron for LBW infants

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.